58,898 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Polymer Capital Management HK LTD

Polymer Capital Management HK LTD acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 58,898 shares of the company’s stock, valued at approximately $1,429,000. Polymer Capital Management HK LTD owned approximately 0.06% of Nurix Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NRIX. EP Wealth Advisors LLC acquired a new position in Nurix Therapeutics during the second quarter worth $214,000. Ieq Capital LLC acquired a new position in Nurix Therapeutics in the 2nd quarter valued at about $252,000. E Fund Management Co. Ltd. purchased a new position in shares of Nurix Therapeutics during the second quarter worth $234,000. Edmond DE Rothschild Holding S.A. purchased a new position in Nurix Therapeutics in the 2nd quarter valued at approximately $2,183,000. Finally, BlackRock Inc. acquired a new position in shares of Nurix Therapeutics in the second quarter worth $212,769,000.

Analyst Upgrades and Downgrades

Several research firms recently commented on NRIX. Truist Financial boosted their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Oppenheimer started coverage on Nurix Therapeutics in a research report on Monday, June 29th. They set an “outperform” rating and a $28.00 price objective for the company. Robert W. Baird raised their target price on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright raised their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.21.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 4,356 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total value of $108,900.00. Following the completion of the sale, the insider directly owned 117,227 shares of the company’s stock, valued at $2,930,675. This trade represents a 3.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares in the company, valued at $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 25,314 shares of company stock valued at $589,361. Corporate insiders own 6.70% of the company’s stock.

Nurix Therapeutics Price Performance

NRIX stock opened at $26.72 on Monday. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -7.74 and a beta of 1.79. The company has a fifty day moving average price of $23.43 and a 200 day moving average price of $18.65. Nurix Therapeutics, Inc. has a 12 month low of $8.19 and a 12 month high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The company had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $15.29 million. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.